Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 357-376

  Albo, Daniel ^a   Farrow, Buckminster ^a   Berger, David H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETALOCIB; FANCONI ANEMIA GROUP C PROTEIN; GEFITINIB; GEMCITABINE; LIPOXYGENASE INHIBITOR; MACROPHAGE MIGRATION INHIBITION FACTOR; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; MESOTHELIN; MICRORNA; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PROTEIN KINASE LKB1; PROTEIN P16; SORAFENIB; TANOMASTAT; THALIDOMIDE; TIPIFARNIB; TRYPSINOGEN; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ASTHENIA; BLEEDING; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; EVENING DOSAGE; FAMILY HISTORY; FEVER; HEADACHE; HUMAN; HYPERTENSION; IMMUNOLOGY; METHYLATION; MISMATCH REPAIR; MOLECULAR BIOLOGY; ONCOGENE; PANCREAS CANCER; PANCREAS JUICE; RASH; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; SMOKING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; CYCLOOXYGENASE 2 INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; MOLECULAR BIOLOGY; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41049108469     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.12.004     Document Type: Review

References (83)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin 49 1 (1999) 8-31
2. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117 6 (1999) 1463-1484
3. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 23 20 (2005) 4524-4531
4. Greenhalf W., and Neoptolemos J.P. Increasing survival rates of patients with pancreatic cancer by earlier identification. Nat Clin Pract Oncol 3 7 (2006) 346-347
5. Chari S.T., Leibson C.L., Rabe K.G., et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129 2 (2005) 504-511
6. Howes N., Lerch M.M., Greenhalf W., et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2 3 (2004) 252-261
7. Brand R.E., and Lynch H.T. Hereditary pancreatic adenocarcinoma. A clinical perspective. Med Clin North Am 84 3 (2000) 665-675
8. Chang K., Pastan I., and Willingham M.C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50 3 (1992) 373-381
9. Argani P., Iacobuzio-Donahue C., Ryu B., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7 12 (2001) 3862-3868
10. Koopmann J., Buckhaults P., Brown D.A., et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10 7 (2004) 2386-2392
11. Jones J.B., Song J.J., Hempen P.M., et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res 61 4 (2001) 1299-1304
12. Maitra A., Cohen Y., Gillespie S.E., et al. The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 14 5 (2004) 812-819
13. Peng D.F., Kanai Y., Sawada M., et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27 6 (2006) 1160-1168
14. Esquela-Kerscher A., and Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6 4 (2006) 259-269
15. Bloomston M., Frankel W.L., Petrocca F., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297 17 (2007) 1901-1908
16. Hruban R.H., Goggins M., Parsons J., et al. Progression model for pancreatic cancer. Clin Cancer Res 6 8 (2000) 2969-2972
17. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 21 3 (2000) 505-515
18. Bloomston M., Zervos E.E., and Rosemurgy II A.S. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 9 7 (2002) 668-674
19. Bramhall S.R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 2 (2002) 161-167
20. Bramhall S.R., Rosemurgy A., Brown P.D., et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19 15 (2001) 3447-3455
21. Gatto C., Rieppi M., Borsotti P., et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 5 11 (1999) 3603-3607
22. Erlichman C., Adjei A.A., Alberts S.R., et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol 12 3 (2001) 389-395
23. Heath E.I., O'Reilly S., Humphrey R., et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 48 4 (2001) 269-274
24. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 1 (1999) 9-22
25. Itakura J., Ishiwata T., Friess H., et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3 8 (1997) 1309-1316
26. Seo Y., Baba H., Fukuda T., et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 10 (2000) 2239-2245
27. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 3 (2001) 843-850
28. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19 3 (2001) 851-856
29. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
30. Hurwitz H, Fehrenbacher L, Cartwright T. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Paper Presented at the Annual Meeting of the American Society of Clinical Oncology. Chicago, May 31-June 3, 2003.
31. Kindler HL, Lester E. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC). Paper Presented at the Annual Meeting of the American Society of Clinical Oncology. Chicago, May 31-June 3, 2003.
32. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 6 (1997) 2403-2413
33. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 7 (2006) 1145-1151
34. Okami J., Yamamoto H., Fujiwara Y., et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5 8 (1999) 2018-2024
35. Xiong H, Plunkett W, Wolff R. Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Paper Presented at the Annual Meeting of the American Cancer Society. Orlando (FL), May 18-21, 2002.
36. Smith S, Burris H, Loehrer P. Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Paper Presented at the Annual Meeting of the American Society of Clinical Oncology. Chicago, May 31-June 3, 2003.
37. Brophy J.M. Cardiovascular risk associated with celecoxib. N Engl J Med 352 25 (2005) 2648-2650 author reply 2648-50
38. Tong W.G., Ding X.Z., Witt R.C., et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1 11 (2002) 929-935
39. Schwartz G, Budman D, Endres S, et al. Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPARc) (abstract 343). Paper Presented at the Annual Meeting of the American Society of Clinical Oncology. Orlando (FL), May 18-21, 2002.
40. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 9 (1994) 4082-4085
41. Udagawa T., Verheul H.M., and D'Amato R.J. Thalidomide and analogues. In: Teicher B.A. (Ed). Antiangiogenic agents in cancer therapy (1999), Humana Press, Totowa (NJ) 263-274
42. Figg W.D., Reed E., Green S., et al. Thalidomide: a prodrug that inhibits angiogenesis. In: Teicher B.A. (Ed). Antiangiogenic agents in cancer therapy (1999), Humana Press, Totowa (NJ) 407-422
43. Densmore J., Fox J., Kannarkat G., et al. A phase I/II trial of weekly gemcitabine with celecoxib and thalidomide for patients with advanced pancreatic cancer. J Clin Oncol 23 Suppl (2005) 4241
44. Xiong H.Q., and Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 5 Suppl 14 (2002) 31-37
45. Ueda S., Ogata S., Tsuda H., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29 1 (2004) E1-E8
46. Robert F., Blumenschein G., Herbst R.S., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23 36 (2005) 9089-9096
47. Bourhis J., Rivera F., Mesia R., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 18 (2006) 2866-2872
48. Xiong H.Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22 13 (2004) 2610-2616
49. Available at: http://www.cancer.gov.
50. Graeven U., Kremer B., Sudhoff T., et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94 9 (2006) 1293-1299
51. Strumberg D, Scheulen ME, Hilger RA, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). 2006 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 2006;24(Suppl 18):12504.
52. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 Suppl 18 (2001) 32S-40S
53. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19 13 (2001) 3267-3279
54. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 15 (2007) 1960-1966
55. Blaszkowsky L.S., Kulke R.H., Ryan D.P., et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. 2005 ASCO Annal Meedint Proceedings. J Clin Oncol 23 Suppl 16 (2005) 4099
56. Iannitti D., Dipetrillo T., Akerman P., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28 6 (2005) 570-575
57. Yip-Schneider M.T., and Schmidt C.M. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Pancreas 27 4 (2003) 337-344
58. Gysin S., Lee S.H., Dean N.M., et al. Pharmacologic inhibition of RAF->MEK->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res 65 11 (2005) 4870-4880
59. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30 5 Suppl 16 (2003) 105-116
60. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 22 (2004) 4456-4462
61. Strumberg D., Clark J.W., Awada A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 4 (2007) 426-437
62. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12 1 (2006) 144-151
63. Appels N.M., Beijnen J.H., and Schellens J.H. Development of farnesyl transferase inhibitors: a review. Oncologist 10 8 (2005) 565-578
64. Crul M., de Klerk G.J., Swart M., et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20 11 (2002) 2726-2735
65. Macdonald J.S., McCoy S., Whitehead R.P., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 23 5 (2005) 485-487
66. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma 4 Suppl 1 (2003) S30-S35
67. Kim E.S., Kies M.S., Fossella F.V., et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104 3 (2005) 561-569
68. Ryan D.P., Eder Jr. J.P., Puchlaski T., et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 10 7 (2004) 2222-2230
69. Kim I.A., Fernandes A.T., Gupta A.K., et al. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev 23 3-4 (2004) 227-236
70. Matsui Y., Goto M., Iwakawa M., et al. Modified radiosensitivity of pancreatic cancer xenografts by farnesyl protein transferase inhibitor and MEK inhibitor. Oncol Rep 10 5 (2003) 1525-1528
71. Cengel K.A., Deutsch E., Stephens T.C., et al. Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines. Cancer Biol Ther 5 9 (2006) 1206-1210
72. Martin N.E., Brunner T.B., Kiel K.D., et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 10 16 (2004) 5447-5454
73. Wobser M., Keikavoussi P., Kunzmann V., et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55 10 (2006) 1294-1298
74. Gjertsen M.K., Saeterdal I., Saeboe-Larssen S., et al. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 81 1 (2003) 43-50
75. Yamamoto K., Ueno T., Kawaoka T., et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25 5 (2005) 3575-3579
76. Petrulio C.A., and Kaufman H.L. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 5 1 (2006) 9-19
77. Yamamoto K., Mine T., Katagiri K., et al. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep 13 5 (2005) 874-883
78. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 5 6 (2005) 459-467
79. Yanagimoto H., Mine T., Yamamoto K., et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98 4 (2007) 605-611
80. Thomas A.M., Santarsiero L.M., Lutz E.R., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200 3 (2004) 297-306
81. Hung C.F., Calizo R., Tsai Y.C., et al. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 25 1 (2007) 127-135
82. Brett B.T., Smith S.C., Bouvier C.V., et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20 20 (2002) 4225-4231
83. Gilliam A.D., and Watson S.A. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 7 3 (2007) 397-404